No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/50 7/51 10/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/52 2/51 10/54 11/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/49 0/47 1/52 2/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 0/50 2/48 1/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 20/49 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 6/49 12/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 21/50 36/49 29/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 1/59 0/60 4/60
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 0/60 0/59 3/60
|
Neoplastic Lesions
|
No
|
TR-334
|
121-88-0 |
2-Amino-5-nitrophenol |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-334
|
121-88-0 |
2-Amino-5-nitrophenol |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-334
|
121-88-0 |
2-Amino-5-nitrophenol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
No Evidence |
Equivocal Evidence |
ADENOMA 2/50 1/50 7/50 OR CARCINOMA 1/50 2/50 0/50 COMBINED 3/50 3/50 7/50
|
May Have Been Related
|
Yes
|
TR-334
|
121-88-0 |
2-Amino-5-nitrophenol |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 10/50 3/49
|
Neoplastic Lesions
|
No
|
TR-334
|
121-88-0 |
2-Amino-5-nitrophenol |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Some Evidence |
Equivocal Evidence |
ADENOMA 3/50 2/50 1/50 OR CARCINOMA 0/50 0/50 4/50 COMBINED 3/50 2/50 5/50
|
May Have Been Related
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Female |
Gavage |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 1/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 18/50 25/50 22/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/50 2/50 2/49 COMBINED 18/50 27/50 24/49
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 7/50 16/50 3/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 3/50 7/49 4/50 OR CARCINOMA 1/50 5/49 0/50 COMBINED 4/50 12/49 4/50
|
Neoplastic Lesions
|
Yes
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 2/50 13/50 6/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Female |
Gavage |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 15/49 24/50 25/50
|
Neoplastic Lesions
|
No
|
TR-332
|
149-30-4 |
2-Mercaptobenzothiazole |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 4/50 4/50 OR CARCINOMA 1/50 2/50 1/50 COMBINED 1/50 6/50 5/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Positive |
Positive |
ADENOMA 2/50 3/50 12/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 3/50 8/50 8/48
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
FIBROADENOMA 15/50 21/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Positive |
Positive |
ADENOMA 1/47 3/47 7/49
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Pancreas Islet Cell
|
Positive |
Positive |
ADENOMA 0/50 6/49 2/47 CARCINOMA 0/50 1/49 0/47 COMBINED 0/50 7/49 2/47
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Female |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
FIBROMA 0/50 1/50 3/50 OR FIBROSARCOMA 2/50 0/50 2/50 COMBINED 2/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Rats |
F344/N |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
FIBROMA 3/50 3/50 9/50 OR FIBROSARCOMA 0/50 3/50 3/50 COMBINED 3/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-251
|
26471-62-5 |
2,4- & 2,6-Toluene diisocyanate |
Mice |
B6C3F1 |
Female |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOMA 0/50 1/50 2/50 OR HEMANGIOSARCOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-458
|
85-68-7 |
Butyl benzyl phthalate |
Rats |
F344/N |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
Yes
|
TR-458
|
85-68-7 |
Butyl benzyl phthalate |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 3/50 2/49 3/50 10/50 OR CARCINOMA 0/50 0/49 0/50 1/50 COMBINED 3/50 2/49 3/50 11/50
|
Neoplastic Lesions
|
No
|
TR-458
|
85-68-7 |
Butyl benzyl phthalate |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Equivocal Evidence |
Equivocal Evidence |
TRANSITIONAL CELL PAPILLOMA 1/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 9/49 10/50; CARCINOMA 9/50 17/49 20/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/50 3/49 11/50; CARCINOMA 0/50 3/49 5/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 2/50 21/50 23/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 3/50 5/50
|
May Have Been Related
|
Yes
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/49 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-304
|
115-28-6 |
Chlorendic acid |
Rats |
F344/N |
Male |
Dosed-Feed |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 8/50 4/50
|
May Have Been Related
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-196
|
87-29-6 |
Cinnamyl anthranilate |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Positive |
Positive |
ADENOMA OR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (1/49, 0/50, 5/50, 9/50, 5/48); hepatocellular carcinoma (0/49, 0/50, 0/50, 0/50, 8/48); hepatocellular adenoma or carcinoma (combined) (1/49, 0/50, 5/50, 9/50, 13/48)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 0/50, 1/50, 1/50, 13/49); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 2/49); hepatocellular adenoma or carcinoma (combined) (0/50, 0/50, 1/50, 1/50, 14/49)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 2/50, 0/50, 1/50, 6/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50, 6/50); hepatocellular adenoma or carcinoma (combined) (0/50, 2/50, 0/50, 1/50, 12/50)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma (0/50, 1/49, 0/50, 3/50, 8/49); hepatocellular carcinoma (1/50, 0/49, 0/50, 0/50, 3/49); hepatocellular adenoma or carcinoma (combined) (1/50, 1/49, 0/50, 3/50, 11/49)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma or carcinoma (combined) (0/49, 0/50, 0/50, 2/50, 1/48)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma or carcinoma (combined) (0/50, 0/50, 0/50, 1/50, 2/47)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma (1/49, 4/50, 5/50, 23/50, 30/50); acinar carcinoma (0/49, 1/50, 0/50, 1/50, 5/50); acinar adenoma or carcinoma (combined) (1/49, 5/50, 5/50, 23/50, 33/50)
|
Neoplastic Lesions
|
Yes
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
acinar adenoma (10/50, 7/49, 8/50, 36/50, 22/49); acinar carcinoma (0/50, 0/49, 0/50, 3/50, 1/49); acinar adenoma or carcinoma (combined) (10/50, 7/49, 8/50, 38/50, 22/49)
|
Neoplastic Lesions
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Testis
|
Clear Evidence |
Equivocal Evidence |
interstitial cell, adenoma (7/50, 3/50, 3/50, 6/50, 15/50)
|
May Have Been Related
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Clear Evidence |
Equivocal Evidence |
adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (3/50, 1/50, 1/50, 3/50, 7/50)
|
May Have Been Related
|
No
|
TR-601
|
117-81-7 |
Di(2-ethylhexyl) Phthalate |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Clear Evidence |
Clear Evidence |
adenoma, adenocarcinoma, squamous cell carcinoma, or squamous cell papilloma (combined) (2/50, 4/50, 1/50, 6/50, 13/50)
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 5/49 6/49 18/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 11/50 20/50 21/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Equivocal Evidence |
Equivocal Evidence |
FIBROADENOMA 9/50 19/50 16/50 OR ADENOMA 0/50 0/50 1/50 COMBINED 9/50 19/50 17/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Female |
Gavage |
Pancreas Acinar Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 2/50 3/47 6/50
|
Neoplastic Lesions
|
Yes
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 25/50 30/49 33/50
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
HEPATOCELLULAR CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
HEPATOCELLULAR CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-026
|
1836-75-5 |
Nitrofen |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Liver)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-026
|
1836-75-5 |
Nitrofen |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Liver)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Unspecified
|
Clear Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Unspecified
|
Some Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
Postweaning: hepatocellular carcinoma (1/50, 1/50, 3/49)
|
May Have Been Related
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Equivocal Evidence |
Perinatal + Postweaning: hepatocellular carcinoma (1/50, 0/50, 4/50)
|
May Have Been Related
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Perinatal + Postweaning: hepatocellular adenoma (0/50, 1/50, 5/50, 10/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 4/50); hepatocellular adenoma or carcinoma (0/50, 1/50, 5/50, 12/50)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
Postweaning: hepatocellular adenoma (0/50, 0/50, 7/50, 11/50); hepatocellular carcinoma (0/50, 0/50, 0/50, 0/50); hepatocellular adenoma or carcinoma (0/50, 0/50, 7/50,11/50)
|
Neoplastic Lesions
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
Postweaning: acinar cell adenoma (3/50, 28/50, 26/50, 32/50); acinar cell adenocarcinoma (0/50, 3/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (3/50, 29/50, 26/50, 32/50)
|
Neoplastic Lesions
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
Perinatal + Postweaning: acinar cell adenoma (7/50, 18/50, 30/50, 30/50); acinar cell adenocarcinoma (0/50, 2/50, 1/50, 3/50), acinar cell adenoma or adenocarcinoma (7/50, 20/50, 30/50, 30/50)
|
Neoplastic Lesions
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
Perinatal + Postweaning: acinar cell adenoma (0/50, 0/50, 3/50); acinar cell adenocarcinoma (0/50, 0/50, 2/50); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 5/50)
|
Neoplastic Lesions
|
Yes
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
Postweaning: acinar cell adenoma (0/50, 0/50, 1/49); acinar cell adenocarcinoma (0/50, 0/50, 1/49); acinar cell adenoma or adenocarcinoma (0/50, 0/50, 2/49)
|
Neoplastic Lesions
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Some Evidence |
Equivocal Evidence |
Perinatal + Postweaning: adenocarcinoma (1/50, 3/50, 5/50)
|
May Have Been Related
|
No
|
TR-598
|
335-67-1 |
Perfluorooctanoic acid (PFOA) |
Rats |
Harlan Sprague-Dawley |
Female |
Dosed-Feed |
Uterus
|
Some Evidence |
Equivocal Evidence |
Postweaning: adenocarcinoma (1/50, 5/50, 8/50)
|
May Have Been Related
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53
|
Neoplastic Lesions
|
Yes
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50
|
Neoplastic Lesions
|
No
|
TR-530
|
TEFBINARYMIX |
Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53
|
May Have Been Related
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 1/53 1/53 1/53 11/51 OR CHOLANGIOCARCINOMA 0/53 0/53 2/53 7/53 9/51
|
Neoplastic Lesions
|
No
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/53 2/53 20/53
|
Neoplastic Lesions
|
Yes
|
TR-526
|
TEFDIOXINMIX |
Toxic equivalency factor evaluation (Dioxin mixture) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/52 1/53 2/53 2/53 0/51
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/52 0/51 0/52 0/52 3/52 36/49 29/49 adenoma 0/52 1/51 1/52 4/52 12/52 24/49 1/49 hepatocholangioma 0/52 0/51 0/52 0/52 0/52 4/49 0/49
|
Neoplastic Lesions
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/51 0/52 0/52 0/52 0/52 20/50 0/50
|
Neoplastic Lesions
|
Yes
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
Adenoma 0/52 0/52 0/52 2/52 3/52 1/47 0/49 adenoma or carcinoma 0/50 0/52 0/52 2/52 3/52 2/47 0/49
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Equivocal Evidence |
Squamous cell carcinoma: 0/52 0/52 3/52 1/52 1/52 0/52 1/50
|
May Have Been Related
|
No
|
TR-559
|
31508-00-6 |
Toxic equivalency factor evaluation (PCB 118) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus
|
Clear Evidence |
Clear Evidence |
Carcinoma 2/52 2/52 1/52 3/52 4/52 3/52 11/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50
|
Neoplastic Lesions
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Some Evidence |
Equivocal Evidence |
CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Some Evidence |
Some Evidence |
(ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50
|
Neoplastic Lesions
|
Yes
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49
|
May Have Been Related
|
No
|
TR-525
|
57117-31-4 |
Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Some Evidence |
Equivocal Evidence |
CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Equivocal Evidence |
HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50
|
Neoplastic Lesions
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50
|
Neoplastic Lesions
|
Yes
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49
|
May Have Been Related
|
No
|
TR-521
|
1746-01-6 |
Toxic equivalency factor evaluation (TCDD) |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50
|
Neoplastic Lesions
|